The human IGF-I gene has six exons, four of which are alternatively spliced. Variations in splicing involving exon 5 may occur, depending on the tissue type and hormonal environment. To study the regulation of splicing to IGF-I exon 5, we established an in vitro splicing assay, using a model pre-mRNA containing IGF-I exons 4 and 5 and part of the intervening intron. Using a series of deletion mutants, we identified an 18-nucleotide purine-rich splicing enhancer in exon 5 that increases the splicing efficiency of the upstream intron from 6 to 35%. We show that the serinearginine protein splicing factor-2/alternative splicing factor specifically promotes splicing in cultured cells and in vitro and is recruited to the spliceosome in an enhancerspecific manner. Our findings are consistent with a role for splicing factor-2/alternative splicing factor in the regulation of splicing of IGF-I alternative exon 5 via a purine-rich exonic splicing enhancer. (Endocrinology 143: 146 -154,  2002) 
OL-IGF-INT4-2809S (5Ј-TGCATGTGGGTGGCTCTTCCCAGGTGAC-CCA) and E5-557A (5Ј-CCTTGCCTCTGTCTGTTTAAT) were used to make a fragment containing 221 bp of the 3Ј end of the downstream intron and 218 bp of exon 5. A third PCR, using SP6-E4-493S and E5-557A, in the presence of both amplified fragments, assembled the template. The product was cloned into pCR-blunt (Invitrogen, Carlsbad, CA) and verified by sequencing. Templates for in vitro transcription were made by further PCRs using a primer to the SP6 promoter and the following downstream primers: E5-630A (5Ј-TCCTTCTCTGAGACT-TCG) for pre-mRNA A; E5-699A (5Ј-CTCTGATCTGCAGACTTGCT) for pre-mRNA B; E5-543A (5Ј-GTTTAATCCTCCTGTCCTTCA) for premRNA C; E5-557A for pre-mRNA D; E5-648A (5Ј-GTGTCTTTGGCCA-ACCTT) for pre-mRNA E; E5-666A (5Ј-TCTGTTCCCCTCCTGGAT) for pre-mRNA F; and E5-684A (5Ј-TTGCTTCTGTCCCCTCCT) for pre-mRNA G. All labeled pre-mRNAs were made with SP6 RNA polymerase using [␣- 32 P]-GTP and gel-purified. The H␤␦6 template has been described (27) .
Splicing reactions
Splicing reactions were performed using 20 fmol of pre-mRNA incubated at 30 C with 48% HeLa nuclear or S100 cytosolic extract, 0.5 mm ATP, 3.2 mm MgCl 2 , 2.6% polyvinyl alcohol and 60 mm KCl. HeLa S100 extracts were prepared as described (28) . Nuclear extracts were purchased from the Computer Cell Culture Center (Mons, Belgium). Twenty picomoles of human recombinant SF2/ASF [expressed in and purified from Escherichia coli (29) ] or SC35 (expressed in baculovirus; a gift from R. Xu) was preincubated in the S100 extract before the complementation reaction. Intermediates and products of the splicing reactions were phenol-extracted and run on 5.5% polyacrylamide gels before autoradiography. Quantification was done by digital photography of the autoradiograph with a Kodak DC210ϩ, followed by analysis with the IMAGE program (Scion, Frederick, MD).
Immunoprecipitations
The antibody to SF2/ASF, mAb96, and control antibody to maltosebinding protein, mAb105, have been described (30) . The antibody to hTra2␤ was kindly provided by Julian Venables and Ian Eperon (31) . Immunoprecipitations were performed as described (32) , with some changes. Briefly, splicing reactions were scaled up to 100 l and incubated for 2 h, then diluted to 500 l with IP150 buffer (50 mm Tris-HCl, pH 8.0; 150 mm NaCl; 0.05% NP40). Antibodies were pre-bound to protein A-Sepharose (Fast Flow, Amersham Pharmacia Biotech, Little Chalfont, Buckinghamshire, UK) in IP150 buffer and then added to splicing reactions and incubated at 4 C for 1 h, before three quick washes in IP150 buffer containing 0.5 mg/ml tRNA. The pellet was resuspended in 10 mm Tris-Cl pH 8.0 and 0.1 mm EDTA, and immunoprecipitated RNA recovered by phenol extraction and ethanol precipitation. The supernatant from the anti-MBP tubes was ethanol precipitated, and 10% of the resuspended material was loaded as a control.
Cotransfections and RNA analyses
An IGF-I minigene containing exons 4, 5, and 6 (pEGFP-IGF-F1) was made. A PCR fragment containing exon 4 (171 bp), intron 4 (1505 bp), exon 5 up to the first polyadenylation/cleavage site (218 bp) and the 5Ј end of intron 5 (198 bp) was made with primers EcoRI-MOD4-2244S (5Ј-GGAAT-TCCGGGTATGGCTCCAGCAGT) and NotI-MODINT3238A (5Ј-ATAA-GAATGCGGCCGCACATATATTGACATAGGCAATTCT) using Expand High Fidelity polymerase (Roche Molecular Biochemicals, Mannheim, Germany) to amplify human genomic DNA. A second PCR fragment containing the 3Ј end of intron 5 (284 bp) and exon 6 (399 bp) was made with primers NotI-MODINT3367S (5Ј-ATAAGAATGCGGCCGCATA-GAAGCAGATGAATCAACT) and SacII-MOD6A (5Ј-GCTGAGC-CGCGGAGTGCAACTGGATCTATACAA). The fragments were assembled via the NotI sites and cloned into the EcoRI and SacII sites of pEGFP-C1 (CLONTECH Laboratories, Inc., Palo Alto, CA). The construction was verified by sequencing on both strands and was used as The length of the 3Ј exon is given after each deletion. B, Splicing reactions using IGF4 -5 pre-mRNAs. The radiolabeled pre-mRNA substrates represented in Fig. 2A (and as indicated by letters above the lanes) were incubated in HeLa nuclear extracts for 1 or 2 h (as shown above the lanes). The reactions were deproteinized, RNA extracted and run on denaturing polyacrylamide gels. The identity of the pre-mRNA, intron-lariat, and mRNA bands is indicated by symbols on the right of the autoradiograph, with the mRNAs also indicated by the square bracket.
a reporter in cotransfection experiments (33) with plasmids pCG-SF2 (expressing SF2/ASF) or pCG-SC35 (expressing SC35). Briefly, 2 g of pEGFP-IGF-F1, with or without 2 g of pCG-SF2 or pCG-SC35, was transfected into approximately 75% confluent HeLa cells plated in 3-cm diameter wells using Fugene 6 (Roche Molecular Biochemicals), according to the manufacturer's protocol. Total RNA was harvested 24 h later using the TRI reagent (Sigma, St. Louis, MO), and RT-PCR was performed as described (8) . Splicing to exon 5 was assayed with primers EGFP-1323S (5Ј-GTACAAGTCCGGACTCAGAT) and E5-557A (5Ј-CCTTGCCTCTGTCTGTTTAAT). Splicing to exon 6 was assayed with primers EGFP-1323S and E6-669A (5Ј-CTGCGGTGGCATGTCAC-TCTT). Reaction products were resolved on 6% nondenaturing polyacrylamide gels, photographed and scanned with a Scanjet 5370C (Hewlett-Packard Co., Palo Alto, CA) and quantified through the IMAGE program. Muscle biopsies were obtained from patients after written informed consent or assent and approval of the study by the local research ethics committee and were subjected to RNA extraction, RT-PCR, Southern blotting and quantification, as described (8) . Serum IGF-I was assayed by an in-house RIA (normal range 108-369 ng/ml; interassay and intraassay coefficient of variation Ͻ10%).
Results

Splicing of IGF-I exon 5 in vitro
We first constructed an IGF-I splicing substrate consisting of exons 4 and 5 and the entire intervening intron. This pre-mRNA was very unstable under standard in vitro splicing conditions (data not shown). We therefore made another IGF-I pre-mRNA substrate with a 1221-bp deletion in the intron, IGF4 -5 ( Fig. 2A) . The construct was made by overlap extension PCR. The size and position of the deletion was designed to allow sufficient intronic sequence so that disruption of the splice sites was unlikely, but not too much to make the pre-mRNA difficult to manipulate or subject to degradation. In particular, the branchsite of the intron has not been mapped, so a longer section at the 3Ј end of the intron was retained. This substrate spliced in vitro with little degradation (Fig. 2B, lane 9) . We then generated a deletion series from the 3Ј end of exon 5 ( Fig. 2A) . The initial deletions were large and designed to examine regions of exon 5 for elements affecting splicing efficiency. An increase in splicing efficiency between pre-mRNAs A and B was observed (Fig.  2B , compare lanes 2 and 3 with lanes 4 and 5). Substrates C and D gave clear spliced products at 2 h (lanes 7 and 9), but the kinetics of mRNA appearance was slower than B at 1 h (compare lanes 6 and 8 to lane 4).
To define elements within the 69-nt segment between A and B, this region was subdivided into three segments (E, F, and G; Fig. 3A) . A significant improvement in splicing efficiency was seen between E and F pre-mRNAs (compare lanes 4 and 6; Fig. 3B ), but not between A and E pre-mRNAs (compare lanes 2 and 4, Fig. 3B ). In three independent experiments, the mean ratio of mRNA to pre-mRNA after 1 and 2 h of splicing increased from 3% (se 0.5%) and 6% (se 1%) for pre-mRNAs A and E to 35% (se 5%) for pre-mRNA F ( 
SF2/ASF promotes splicing of IGF-I exon 5
Several SR proteins in mammalian (34) and Drosophila (35) nuclear extracts bind purine-rich exonic elements to promote splicing. S100 cytosolic extracts were used to identify transacting factors required for promotion of splicing to exon 5. These extracts are not competent for splicing because they lack SR proteins (36) . We complemented S100 extracts with either of two recombinant SR proteins: SF2/ASF and SC35. Both SF2/ASF and SC35 were able to restore splicing of a ␤-globin pre-mRNA in an S100 extract (Fig. 4, lanes 3 and 4) . We exploited this system to study the specificity of action of SR proteins on IGF pre-mRNA in vitro splicing. We incubated pre-mRNAs A, E, and F in nuclear and S100 extracts. As before, pre-mRNAs A and E showed only traces of splicing in nuclear extract (lanes 5 and 9), whereas pre-mRNA F was efficiently spliced (lane 13). None of the pre-mRNAs spliced in the S100 extract alone (lanes 2, 10, and 14; nonspecific degradation of the pre-mRNA is seen in lane 6). However, pre-mRNA F spliced efficiently in an S100 extract complemented with SF2/ASF (lane 15), but not in an S100 extract complemented with SC35 (lane 16). This indicated a specific requirement for SF2/ASF and the purine-rich enhancer for in vitro splicing to IGF-I exon 5 and ruled out a nonspecific effect of exon length on splicing of the pre-mRNAs. SF2/ASF was unable to promote splicing of the IGF4 -5 pre-mRNA in the absence of this enhancer (lane 11). This experiment was independently performed twice with similar results.
SF2/ASF is recruited to the IGF-I pre-mRNA spliceosome in an enhancer-specific manner
Tra2 is a Drosophila SR protein that regulates alternative splicing of Doublesex pre-mRNA via binding to nonpurinerich repeat elements and a purine-rich enhancer in Drosophila nuclear extracts and also when added to mammalian nuclear extracts. Drosophila Tra2 binds the exonic enhancers in a cooperative manner with SR proteins, including SF2/ASF (35) . hTra2␣ (37) and hTra2␤ (38) are human homologs of Tra2 and also promote sequence-specific splicing in mammalian pre-mRNA (39) . To test whether similar cooperation may take place for the IGF-I enhancer, we assayed for the presence of SF2/ASF and hTra2␤ in the spliceosome by immunoprecipitations with anti-SF2/ASF and anti-hTra2␤. First, pre-mRNAs E and F were incubated in nuclear extracts for 2 h. Next, specific antibodies were added to the reactions and immunoprecipitations were performed using protein A-Sepharose. If SF2/ASF or hTra2␤ are present in spliceosomes assembling on IGF pre-mRNAs, then spliceosomes and labeled pre-mRNA should be coimmunoprecipitated. The pellets containing labeled RNAs were deproteinized and the RNA run on polyacrylamide gels and visualized by autoradiography. The results showed that enhancer-containing pre-mRNA F and mRNA were immunoprecipitated with anti-SF2/ASF or anti-hTra2␤ (Fig. 5, lanes 7 and 8) , whereas only background levels were obtained with the control anti-MBP antibody (lane 6). By contrast, in the absence of the enhancer, pre-mRNA E was immunoprecipitated at background levels only by anti-SF2/ASF (lane 3). Antibodies to hTra2␤ immunoprecipitated pre-mRNA E (i.e. in the absence of the enhancer) at levels higher than background (lane 4; and on overexposed blots, data not shown). This experiment was performed independently four times with similar results. We conclude that hTra2␤ is present in the IGF-I spliceosome, but not in an enhancer-dependent manner and it is unlikely that a cooperative interaction between SF2/ASF and hTra2␤ occurs at the IGF-I enhancer.
FIG. 4. S100-complementation
reactions with IGF4 -5 substrates. Pre-mRNAs A, E, and F were incubated for 2 h in either nuclear extract (NE), or S100 extract (S100). Some S100 reactions were complemented with SR proteins SF2/ASF (SF2) or SC35. The extracts and SR proteins used in each reaction are indicated by ϩ signs above the lanes. ␤-globin pre-mRNA (H␤␦6) was used as a control in lanes 1-4. The pre-mRNAs used are indicated above the lanes. The identity of the IGF pre-mRNA, lariatintermediate, lariat-product and mRNA bands are given on the right of the autoradiograph, with the mRNA bands also shown as a square bracket. The identity of the ␤-globin pre-mRNA, mRNA and 5Ј exon intermediate bands is given on the left of the autoradiograph.
Overexpression of SF2/ASF in cultured cells promotes inclusion of exon 5
To this point, experiments had been performed in vitro in a cell-free system. To show that regulation of splicing to IGF-I exon 5 was regulated by SF2/ASF in living cells, cotransfection experiments in cultured HeLa cells were performed. We designed and constructed an IGF-I minigene, pEGFP-IGF-F1, in a eukaryotic expression plasmid. Note that this minigene was not subject to the same size limitations as the templates used for in vitro splicing and contained the entire intron between exons 4 and 5, and well as exon 6 and parts of the intron between exons 5 and 6. HeLa cells were transfected with pEGFP-IGF-F1 with or without cotransfection with plasmids expressing SF2/ASF (pCG-SF2) or SC35 (pCG-SC35). Splicing via exon 5 was very low in cells expressing the IGF-I minigene alone (Fig. 6A, lane 7) , whereas splicing via exon 6 was clearly detected (lane 11). When SF2/ASF was over-expressed, splicing via exon 5 inclusion was promoted (lane 8), with a mean change of 4.7-fold over three separate experiments (P ϭ 0.004, two-tailed t test) (Fig.  6B) . Overexpression of SC35 also promoted exon 5 inclusion, but less so (mean change of 3.6-fold; P ϭ 0.03). In vitro, SC35 did not promote splicing to exon 5 via the purine-rich sequence in pre-mRNA F (Fig. 4) . Therefore, it is likely that the results in cultured cells reflect the additional exon 5 and downstream intronic sequences present in the minigene (not present in pre-mRNA F) and the presence of SC35-dependent enhancers in the additional sequences.
Regulation of exon 5 inclusion in human muscle
To investigate whether disordered expression of IGF-I may be implicated in clinical situations associated with muscle abnormalities, we examined the regulation of the IGF-I isoforms at the mRNA level in muscle biopsies available from studies of 20 patients. Ten patients had GH deficiency and muscle biopsies were performed at baseline, and repeated 6 months after GH treatment (n ϭ 5 patients) or placebo treatment (n ϭ 5 patients). Ten other patients were treated in an intensive care unit and had muscle biopsies at baseline and repeated 4 and 8 d later, as part of a study of intensive care unit (ICU)-related myopathy. IGF-I mRNAs containing exon 5 or 6 were measured by semiquantitative duplex RT-PCR using a glyceraldehyde phosphate dehydrogenase (GAPDH) PCR product as a standard.
In the group of patients with GH deficiency, GH-treated patients had increased relative IGF-I exon 5 levels (for representative data, see Fig. 7A , compare lane 1 with lane 2 and lane 3 with lane 4). Placebo-treated patients showed less marked changes in IGF-I exon 5 levels (lanes 6 -11). As a group, GH-treated patients had a significant 10.0-fold increase (se 2.9-fold) in relative inclusion of IGF-I exon 5 compared with baseline, compared with a 2.5-fold increase in the placebo-treated patients (se 1.1-fold) (Fig. 7B , solid bars; P ϭ 0.032; two-tailed t test). Note that one patient in the GHtreated group, who showed no response by any criteria (including the serum IGF-I level, which failed to rise into the normal range) and who had a drop in muscle IGF-I exon 5 levels, was excluded from all analyses because we question the compliance of the patient with GH treatment. At baseline, there was no difference in age or body mass index between the GH-treated and the placebo-treated group (mean age 45 compared with 43.6 yr; mean body mass index 30 compared with 30.6 kg/m 2 ). The GH-treated group were all male, whereas two of the five placebo-treated group were male. The increase in serum IGF-I levels after 6 months was significantly greater in the GH-treated compared with the placebo-treated group (mean rise in serum IGF-I of 441 vs. 45.4 ng/ml; P ϭ 0.0003; two-tailed t test).
The patients in intensive care were heterogeneous with seven admitted after coronary or vascular surgery and three suffering severe sepsis. Four patients (including the three suffering sepsis) had clinical, electrophysiological, and histological evidence of myopathy. Five patients without clinical evidence of myopathy nevertheless had a drop in serum IGF-I levels to below the normal range from a mean of 138.2 ng/ml falling to a mean of 85 ng/ml (P ϭ 0.018; two-tailed paired t test) by the time of the second biopsy. For one patient, no biochemical, electrophysiological, or histological data were available. In all the intensive care patients, the IGF-I mRNA expression patterns were unchanged (Fig. 7B) . IGF-I exon 6-containing transcript levels were similar in all groups (Fig. 7B, open bars) .
Discussion
A purine-rich exonic splicing enhancer in IGF-I exon 5 was identified by in vitro splicing assays with pre-mRNAs harboring systematic deletions in exon 5. This enhancer functioned specifically with SF2/ASF, and overexpression of SF2/ASF in cultured HeLa cells promoted splicing via exon 5 inclusion. Splicing enhancer sequences have been identified in several regulated and constitutive exons, and may be classified into purine rich (40) and nonpurine rich (41) . Enhancers interact with SR proteins, including SF2/ASF (35, (42) (43) (44) (45) (46) (47) (48) . SF2/ASF has high binding affinity for certain purinerich sequences in vitro (49) and, under splicing conditions, SF2/ASF and SC35 function through distinct and degenerate consensus sequences (50 -52) . We analyzed IGF-I exon 5 using matrices for predicting sequences through which SF2/ ASF and SC35 function (50, 52) . The 18-nt extension between pre-mRNAs E and F significantly increases splicing to exon 5. The extended sequence in the F pre-mRNA completes an SF2/ASF high-score heptamer motif (beginning at nt 60; Fig. 8) and adds yet another (beginning at nt 69). For SC35, the extension does not affect the number of high-score motifs present. The matrices show two high-score motifs for SF2/ ASF (beginning at nt 25 and 37) and two for SC35 (beginning at nt 5 and 53) in the part of exon 5 included in pre- mRNA A. However, a score above threshold may not be sufficient for exonic splicing enhancer function, because of the surrounding context, e.g. a juxtaposed silencer, which we are currently unable to predict (52) . Our data are compatible with IGF-I exon 5 being a substrate for SF2/ASF via a short enhancer element, and thus, this mechanism may underlie the control of splicing to this exon.
Another feature of the IGF-I exon 5 sequence is the presence of an alternative 5Ј splice site contained in the last 18 nt of pre-mRNA E. This site is used rarely in a tissue-specific manner in human liver (8) and is used in a human kidney tumor library (GenBank accession no. AI478804), although an equivalent site is commonly used in rodents and rabbits (12, 13, 17) . The presence of this site did not promote in vitro splicing to exon 5, nor was the site used for splicing when an IGF-I minigene was transfected into cultured HeLa cells. These data suggest that this site does not interact with U1 snRNP in HeLa extracts or cultured cells, perhaps due to the lack of a specific splicing activator or presence of an inhibitory factor, although the experiments reported here do not address this question.
We attempted to understand the regulation of IGF-I alternative splicing by examining human muscle biopsies taken during studies in patients with GH deficiency. There was a significant increase in the ratio of exon 5-containing mRNAs in patients after treatment with GH, but not in those treated with placebo. The consequence of changes in splicing to exon 5 or 6 involves the E domain of the IGF-I precursor. The physiological roles of the E domains are unknown, although they are not present in insulin. The E domain encoded by exon 5 has been shown to harbor a mitogenic peptide fragment (22) . Our preliminary experiments suggest the E domains may target the IGF-I precursor peptide to different cellular fates (unpublished data).
We also examined muscle biopsies from a heterogeneous group of intensive care patients, either with electrophysiological and histological evidence of myopathy, or with falls of serum IGF-I levels to below the normal range. GH resistance has been observed in such patients (53) . In the intensive care patients, there was no trend evident in the ratios of muscle IGF-I mRNA isoforms. Our data make it less likely that changes in muscle IGF-I production play a role in ICU myopathy or in the falling IGF-I levels seen in these patients (53) . It is possible that the fall in serum IGF-I in our patients was due to reduced liver production, as has been shown in rodent models (see references cited in 53) and by liverspecific IGF-I deletions in mice (54) .
Several studies have investigated alternative splicing in the context of skeletal muscle differentiation, and in most cases this regulated expression involves exons that undergo skeletal muscle-specific inclusion or exclusion (e.g. in tropomyosin or troponin pre-mRNAs). Some of the factors regulating such exons are CUG-binding protein (55) , SF2/ASF (56), and hnRNP H (57). The main difference between the skeletal muscle differentiation alternative splicing systems and our experiments is that muscle biopsies from the patients presumably represent fully differentiated tissue. Fully differentiated tissue may have a more limited capacity for changing splicing compared with that occurring during muscle differentiation. Also, both IGF-I isoforms are expressed, albeit with varying relative abundance. Thus, the effect of GH in changing IGF-I pre-mRNA splicing in differentiated adult skeletal muscle is quantitative. How the spliceosome is adapted to give qualitative changes in exon selection during muscle differentiation as well as quantitative changes seen in fully differentiated muscle is unclear.
SF2/ASF binding promotes assembly of the splicing machinery (34) and later stages of the splicing reaction (58 -61) . In a well characterized system of alternative splicing, SF2/ ASF binds to the Drosophila doublesex purine-rich enhancer in a cooperative manner with Tra2 (35) . hTra2␤ is one of two human homologs of Tra2 (37, 38) and promotes splicing in a sequence-specific manner (39) . hTra2␤ binds a natural exonic splicing enhancer in a human ␣s tropomyosin alternative exon (Eperon, I. C., personal communication). In our experiments, hTra2␤ was present in the IGF-I spliceosome, but not in an enhancer-dependent manner. By contrast, SF2/ ASF associated with the spliceosome in an enhancer-dependent manner. This observation argues against simultaneous cooperative binding by SF2/ASF and hTra2␤ in the context of the IGF-I exon 5 enhancer but does not exclude the possibility that pre-bound hTra2␤ facilitates the recruitment of SF2/ASF, or that SF2/ASF binds cooperatively with other SR proteins or other RNA-binding proteins.
The activity of SF2/ASF may be regulated by several mechanisms (34, 62) , including phosphorylation by kinases (63) , cellular localization (64) , and varying tissue concentrations (30) . Some studies implicate SR proteins in signalingmediated changes in alternative splicing. Insulin signaling changes splicing involving rat fibronectin exon EIIIB and is associated with increased levels of HRS, the rat homolog of SRp40 (48) . The alternative splicing response to serum stimulation or withdrawal in the mouse SRp20 pre-mRNA involves SF2/ASF and SRp20 (65, 66) . Alternative splicing of CD44 and CD45 pre-mRNAs occurs during cytokineinduced T-cell differentiation, via PKC and Ras pathways (67) (68) (69) . SC35, SF2/ASF and other SR proteins alter CD44 and CD45 splicing (70 -72) .
It is possible that SF2/ASF and the purine-rich enhancer are involved in pathways that control the relative levels of expression of IGF-I isoforms in different tissues (13, 24, 25) and in response to GH in animal or cell culture models (8, 12-14, 17, 26) , with some exceptions (73, 74) . In vitro models for regulated splicing systems are difficult to develop (75) , and hence it has not been possible to test whether SF2/ASF and the enhancer function in hormonally regulated or tissuedependent alternative splicing of IGF-I. However, there are examples of enhancers in other exons with dual function in promoting splicing both in constitutive and regulated contexts (69, 76) . Our working hypothesis, derived from the present work in HeLa cells, is that alterations in the localization, phosphorylation or level of SF2/ASF by cellular signals, such as GH-stimulated pathways, may control IGF-I exon 5 inclusion via interaction with the purine-rich exonic element.
